What does real-time Total Joints market intelligence look like? Every day, SmartTRAK analysts monitor MedTech developments around the world, sorting through the latest news, financial results, product launches and competitor activity to identify what matters most to our subscribers.
But our analysts do more than report the news. They review each development, put it into context and explain what it could mean for the Total Joints market. Whether it’s a new product launch, a company’s financial performance or a shift in the competitive landscape, SmartTRAK helps subscribers understand both what’s happening and why it matters.
Ahead of AAHKS 2026, we’re sharing a selection of recent Total Joints updates compiled and posted in real-time by our analysts over the past week. This sampling offers a glimpse of the timely insights and comprehensive market coverage SmartTRAK delivers every day to help subscribers stay informed and make strategic decisions.
-
Robotic UKA Linked to 46% Lower Odds of Revision vs Manual
A meta-analysis of 34 studies (n=68,196) found robotic vs manual UKA had lower odds of revision (OR 0.54) and complications (OR 0.66), better tibial slope accuracy and modestly higher KSS and OKS, but added 16.1 min of operative time. OS
-
CJR-X Brings Mandatory 90-Day Accountability in 2028
Beginning Jan 2028, CMS' CJR-X model will hold hospitals accountable for 90-day hip, knee and ankle replacement episodes, including post-acute costs. Mandatory nationwide accountability will push hospitals to manage variation in PAC use, complications and total episode spend.
-
Hospitals Begin Building Cost Control Infrastructure Ahead of 2028 CJR-X
SmartTRAK notes early signs of hospital prep for CJR-X cost containment. Navvis, a value-based care enablement company, has launched a CJR-X solution to help hospitals manage joint replacement episode costs, physician alignment and post-acute care ahead of the 2028 mandate.
- Sizing Up Privately Held Maxx Orthopedics
SmartTRAK analysis of reports from CARE Ratings, an Indian credit rating agency, found Maxx Orthopedics’ standalone WW revenue reached $34.3MM in H126. SmartTRAK estimates US revenue at $14.4MM based on historical geographic mix.
- Maxx Orthopedics’ US Growth Contrasts OUS Weakness
Maxx Orthopedics’ standalone CY25 WW revenue decreased -6.8% to $50.2MM, according to CARE Ratings. SmartTRAK estimates US revenue grew by +21.0% to $24.1M, w/ OUS weakness driving the WW decline.
- MicroPort
MicroPort received FDA 510(k) clearance for its cemented EVOLUTION MPX Total Knee System, a rebranded version of its MedalOne TKA, adding PS femoral components, CR and PS tibial inserts, expanded insert thicknesses and patellar sizes.
- MOBIO Primary Knee - b-ONE Ortho
B-One Ortho received FDA 510(k) clearance for its Mobio Total Knee System, adding cemented tibial augments, additional cemented tibial stem extension sizes and new cementless press-fit stem extensions for revision TKA.
- TJO Surpasses 55,000 Implants, Expands ASC Presence
SmartTRAK highlights that TJO reported more than 55K implants have been placed in the US, including 42K+ Klassic Knee implants, which is supported by 12-yr results. ASCs accounted for 32% of their 2026 YTD procedures.
- Medacta
Medacta received FDA 510(k) clearance for line extensions to its GMK TKA system, adding cemented GMK Sphere FULL PE FLEX and FLEX E-CROSS tibial components in 15 sizes and a new oblique titanium stem extension for its GMK Primary Total Knee System
- MicroPort OSR-2000 Robotic TKA Improves Alignment vs Manual
A retro study (n=86) found MicroPort OSR-2000 robotic-assisted TKA had better alignment, less blood loss and better early pain, ROM and KSS vs manual TKA, w/ KSS still higher at 12 mos. Robotic cases took longer, w/ similar stay and complications. J Robot Surg
Want more insights like these? SmartTRAK analysts monitor the Total Joints market every day, providing timely updates and expert analysis on the developments shaping the industry. Click the button to discover what SmartTRAK can do for you.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to mkt experts for inquiries and advisory services. If you would like a demo of what SmartTRAK offers and how we can help increase efficiency, improve productivity and reduce costs for your company, just click here.